Why would a patient with atrial fibrillation who recently underwent percutaneous coronary intervention be prescribed both clopidogrel (generic) and Eliquis (apixaban)?

Why Patients with Atrial Fibrillation After PCI Receive Both Clopidogrel and Eliquis

For patients with atrial fibrillation who recently underwent percutaneous coronary intervention, the combination of clopidogrel and Eliquis (apixaban) is the recommended default strategy because this dual therapy regimen significantly reduces bleeding risk compared to triple therapy while maintaining equivalent protection against thrombotic events. 1

The Core Rationale

Patients in this scenario face two competing thrombotic risks that historically required different medications:

• Atrial fibrillation creates a 4- to 5-fold increased stroke risk requiring anticoagulation 1
• Recent coronary stent placement creates acute stent thrombosis risk requiring antiplatelet therapy 1

The traditional approach of "triple therapy" (anticoagulant + aspirin + clopidogrel) increases major bleeding risk 2- to 3-fold, with absolute bleeding rates reaching 4-12% at one year. 1 Since major bleeding is associated with up to a 5-fold increased risk of death following acute coronary syndrome, minimizing bleeding while preserving ischemic protection is paramount. 1

Evidence Supporting Dual Therapy

Multiple randomized trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) demonstrated that dual therapy with a direct oral anticoagulant plus clopidogrel showed either noninferiority or no significant difference for ischemic endpoints but superior safety compared to triple therapy. 1 None of these trials were individually powered for efficacy endpoints, yet the consistency of bleeding reduction without increased thrombotic events across all trials established the evidence base. 1

The AUGUSTUS trial specifically showed that apixaban plus clopidogrel (without aspirin) reduced major or clinically relevant nonmajor bleeding by 34% compared to vitamin K antagonist therapy, while maintaining similar rates of death and ischemic events. 2, 3

Current Guideline Recommendations

The 2020 ACC Expert Consensus Decision Pathway strongly recommends against routine use of triple therapy for most patients. 1 The default strategy after recent PCI is dual antithrombotic therapy consisting of an anticoagulant and a P2Y12 inhibitor. 1

Specific Medication Selection

• Direct oral anticoagulants (DOACs) are preferred over warfarin because they confer markedly lower bleeding risk 4
• Clopidogrel is the only acceptable P2Y12 inhibitor when combined with anticoagulation; prasugrel and ticagrelor significantly increase bleeding risk and are not recommended 1, 4
• Aspirin should be discontinued at hospital discharge or within 1 week for most patients 1, 5

Duration Algorithm

The treatment regimen follows a structured de-escalation pathway based on time since PCI:

Immediate Post-PCI Period (0-7 days, maximum 30 days)

• Triple therapy (apixaban + clopidogrel + aspirin) is reserved only for patients at highest thrombotic risk with acceptable bleeding risk 1
• Most patients should receive dual therapy (apixaban + clopidogrel) starting at discharge 1, 5

1 Month to 12 Months Post-PCI

• Continue dual therapy with apixaban + clopidogrel 1
• This duration applies regardless of whether the presentation was stable ischemic heart disease (6 months) or acute coronary syndrome (12 months) 1

Beyond 12 Months Post-PCI

• Discontinue clopidogrel and continue apixaban monotherapy 1
• Exception: Selected patients at very high thrombotic risk and low bleeding risk may continue single antiplatelet therapy beyond 12 months at clinician discretion 1

Critical Timing Considerations

The AUGUSTUS trial provided important temporal insights: aspirin use in the first 30 days after PCI resulted in an equal tradeoff between increased severe bleeding (absolute risk difference +0.97%) and reduced severe ischemic events (absolute risk difference -0.91%). 2 However, after 30 days, aspirin continued to increase bleeding (absolute risk difference +1.25%) without significantly reducing ischemic events (absolute risk difference -0.17%). 2 This evidence supports limiting aspirin to the immediate post-PCI period only.

Common Pitfalls to Avoid

• Do not continue aspirin "just to be safe" beyond the initial post-PCI period—this markedly increases bleeding without providing additional thrombotic protection 4
• Do not use prasugrel or ticagrelor in combination with anticoagulation—these agents substantially increase bleeding risk compared to clopidogrel 1, 4
• Do not use reduced-dose apixaban (2.5 mg twice daily) unless the patient meets specific dose-reduction criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 4, 6
• Do not prolong triple therapy beyond the shortest necessary duration—bleeding risk accumulates over time without proportional ischemic benefit 1, 4

Special Considerations for Apixaban Dosing

Apixaban should be dosed at the full stroke-prevention dose (5 mg twice daily) unless dose-reduction criteria are met. 4 In the AUGUSTUS trial, approximately 10% of patients received reduced-dose apixaban (2.5 mg twice daily), but less than half of these patients actually met the dose-reduction criteria. 6 Both appropriately reduced-dose and standard-dose apixaban showed favorable outcomes compared to vitamin K antagonists, with lower bleeding risk and similar ischemic event rates. 6

Bleeding Risk Mitigation

Beyond medication selection, the ACC guidelines recommend:

• Proton pump inhibitors should be routinely prescribed to reduce gastrointestinal bleeding risk 4
• Formal bleeding-risk assessment using the HAS-BLED score at initiation and each follow-up visit 4
• Active correction of modifiable bleeding risk factors including uncontrolled hypertension, excessive alcohol intake, concurrent NSAID use, and anemia 4